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Endothelial nitric oxide synthase (eNOS) is part of a family of three nitric oxide 
synthase (NOS) enzymes that catalyze the production of nitric oxide (NO). NO is a 
gaseous, free-radical signaling molecule that has a variety of cellular and physiological 
functions that range from maintaining cardiovascular homeostasis to neurotransmission. 
The function of NO greatly depends on the concentration and is cell type specific. eNOS 
is the most regulated of the three NOS isoforms and the mechanisms of regulation can be 
through protein-protein interactions and posttranslational modifications. A connection with 
eNOS and the cell cycle has begun to form with recent research identifying eNOS as a 
substrate of cyclin-dependent kinases (CDK). CDKs are one of the regulatory elements in 
cell cycle progression and form a class of serine/threonine kinases. The most commonly 
studied and well understood posttranslational modification of eNOS is phosphorylation. 
This work builds on our laboratory’s discovery of a phosphorylation site – ser600 – on the 
autoinhibitory loop of eNOS. Our work finds a novel connection between phosphorylation 




CHAPTER 1 – INTRODUCTION 
Nitric Oxide and its Physiological Relevance 
Nitric oxide (NO) is a gaseous free-radical molecule that, while short-lived, 
regulates a plethora of physiological functions that are both concentration and 
location/context dependent (1-5). For example, in the nervous system, NO can act as a 
neurotransmitter (4). In the cardiovascular system, NO can act as a vasodilator mediating 
endothelium-based relaxation of blood vessels (1). Additionally, NO can influence 
multiple cellular events ranging from apoptosis to cell cycle arrest (2-5). NO has even been 
implicated in several cancer-related events that include angiogenesis, anti-apoptotic 
mechanisms, tumor cell invasion, and metastasis (5). Overall, NO is a potent bioactive 
molecule that influences an abundance of physiological functions.  
Physiological dysregulation can arise when too much or too little NO is produced. 
A high level of NO is associated with oxidant induced pathogenesis which can result in 
tissue damage and hypertension in the cardiovascular system (6). On the other hand, a low 
level of NO is associated with compromised immune function, increased development of 
cardiovascular issues like hypercholesterolemia, and is linked to exacerbation of diabetic 
symptoms (7).  
NO is a free radical and as such, has high reactivity with just about all molecules. 
Physiologically, NO is not the only free radical that is produced. Some of these radicals 
can be formed from molecules reacting with NO. In fact, there is reasonable variety in the 
physiologically relevant intracellular free radicals, shown in table 1 below (8). Each radical 
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can react with a multitude of molecules ranging from proteins to other signal mediators 
which can alter normal cellular function. 
Table 1: Summary of Different Reactive Oxygen Species and Half-life (8) 
Reactive Species Symbol Half-life 
Superoxide O2
- 10-6 s 
Hydroxyl HO 10-10 s 
Alkoxy RO 10-6 s 




Singlet oxygen 1O2 10
-6 s 
Nitric oxide NO- ~ 7 s* 
Nitrite NO2
- 110 s 
Nitrate NO3
- 5-8 h 
Nitrous acid HNO2 -  
Peroxynitrite ONOO- 10-3 s 
Alkyl 
peroxynitrite 
ROONO -  
Dinitrogen 
trioxide 
N2O3 -  
Dinitrogen 
tetroxide 
N2O4 -  
*- Dependent on environment; for example, can last minutes in air saturated solutions    
Nitric Oxide Synthases 
One of the things that makes NO unique is the short biological half-life it has, which 
means it must be actively produced when necessary by nitric oxide synthase (NOS) 
enzymes. Nitric oxide synthases comprise the class of enzymes that is responsible for the 
production of NO through the conversion of L-arginine to citrulline producing NO (9); this 
reaction is shown below in figure 1. NOS enzymes have three main isoforms, neuronal 
(nNOS; NOS1), inducible (iNOS; NOS2), and endothelial nitric oxide synthases (eNOS; 
NOS3) (10). All three enzymes in the family use the same cofactors including heme, 
tetrahydrobiopterin (BH4), flavin mononucleotide (FMN), flavin adenine dinucleotide 
8 
 
(FAD), zinc, and nicotinamide adenine diphosphate (NADPH). All three enzymes form 
homodimers, which are required for activity (11). All three enzymes carry out the same 
enzymatic reaction that consumes 2 moles of L-arginine, 3 moles of NADPH, 3 moles of 
H+, and 4 moles of O2 to produce 2 moles of L-citrulline, 2 moles of NO, 4 moles of water, 
and 3 moles of NADP+ (figure 1). While all three enzymes can catalyze the same reaction, 
the amount of NO produced varies from isoform to isoform with iNOS producing the most, 
nNOS producing short bursts, and eNOS producing long pulses. The three isoforms also 
have the same general structure, a bidomain protein consisting of a C terminal reductase 
domain and an N terminal oxygenase domain with a calmodulin binding site linking the 
two domains together. Calmodulin binding is necessary to produce NO. One region that is 
not conserved between all three of the enzymes is a stretch of 52-55 amino acids that forms 
an autoinhibitory region between the two domains. This region is present in nNOS and 
eNOS but not iNOS (12). Another difference that exists between the three enzymes is tissue 
expression. Neuronal NOS is expressed constitutively in peripheral and central neurons 
(10). Inducible NOS is not constitutively expressed in cells but can be induced to express 
in nearly all cells as a response to various stimuli, like inflammation (10). Endothelial NOS 
is constitutively expressed most commonly in endothelial cells but can be found in cells 
Figure 1: Nitric Oxide Synthase enzymatic reaction showing conversion from L-arginine to L-
citrulline producing NO. This reaction consumes 2 moles of L-arginine, 3 moles of NADPH, 3 moles 
of H+, and 4 moles of O2 to produce 2 moles of L-citrulline, 2 moles of NO, 4 moles of water, and 3 





like the trophoblasts of the human placenta and kidney tubular epithelial cells (10,13). The 
focus of this study will be on eNOS in endothelial cells.  
Endothelial Nitric Oxide Synthase 
eNOS is primarily expressed in cardiovascular tissue, specifically endothelial cells 
(14). The endothelium comprises the inner lining of all blood vessels and is generally 
divided into two major categories, microvasculature (capillaries) and macrovasculature 
(arterial and venous). For example, the aorta contains macrovascular endothelial cells 
whereas dermal capillaries contain microvascular endothelial cells. The endothelium 
maintains a large amount of eNOS compared to other tissues, this is because NO is potent 
vasodilator and helps to maintain cardiovascular homeostasis (10). eNOS is also unique 
among the NOS enzymes due to the degree of posttranslational modifications involved in 
regulation. Specifically, unlike other NOSs, eNOS is palmitoylated and myristoylated on 
the n-terminus which allows for localization on the plasma membrane (3). Of these two 
modifications, palmitoylation is reversible whereas myristoylation is not. In addition to the 
plasma membrane, eNOS is also found associated with the Golgi apparatus and in the 
cytoplasm of endothelial cells (15). It has been established that eNOS is found in multiple 
subcellular pools – plasma membrane, cytoplasm, and the Golgi apparatus (16). However, 
the full mechanism of how eNOS achieves differential subcellular localization is not 
clearly understood. The consensus in the literature suggests that eNOS must be on the 
plasma membrane in order to achieve maximal enzymatic activity. Membrane localization 
of eNOS allows for diffusion of NO across the membrane onto the underlying smooth 
muscle tissue which results in the signal for vasodilation. The Golgi pool of eNOS is less 
active compared to membrane associated eNOS, likely due to limited access to substrates.  
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Regulation of Endothelial Nitric Oxide Synthase through Phosphorylation 
The most commonly studied form of eNOS regulation is through phosphorylation 
which has resulted in the identification of multiple phosphorylation sites. Each site 
influences eNOS differently resulting in functional enhancement, inhibition, or a change 
in cellular interactions. Most of the identified phosphorylation sites on eNOS are serines 
or threonines. Of them, the first identified and most commonly studied site is ser1177; 
modification at this residue enhances NO production by enhancing electron flow in the 
reductase domain which increases the activity of eNOS (17, 18). Additional known 
activation sites include ser615 and ser633 (19, 20). The most well studied inhibitory site is at 
thr495; phosphorylation at this residue blocks calmodulin association and therefore ablates 
NO output (21). Other phosphorylation sites are present on eNOS but have some ambiguity 
with regards to altering NO output. One site, ser114, has been shown to be inhibitory in vivo 
not in vitro, with the current consensus suggesting that phosphorylation at this residue 
increases association of eNOS to negative cofactors resulting in reduced in vivo activity 
(22, 23). Our lab has recently identified a new phosphorylation site, ser600 (24). Ser600 is 
found in the eNOS autoinhibitory loop near two activating sites, ser615 and ser633. 
Additionally, two tyrosine phosphorylation sites have also been identified on eNOS, tyr81 
and tyr657 (25-27).  Phosphorylation at tyr81 has been shown to be activating while tyr657 is 
thought to be inhibitory (26). Despite the numerous phosphorylation sites, little 
investigation has been done on their regulation during the cell cycle which opens another 
potential avenue understanding for eNOS function and regulation. Known phosphorylation 





Endothelial Nitric Oxide Synthase and the Cell Cycle 
Recently, evidence suggests that eNOS may play a role in cellular proliferation by 
interacting with a variety of genes (28). One study identified that eNOS deficiency in mice 
resulted in reduction of collateral vessel density due to impaired activation of a cell cycle 
gene network during arteriogenesis. Additionally, the same group found that eNOS 
maintains a role in collateral remodeling by regulating cell proliferation (28). Collateral 
blood vessels are abnormal blood vessels which connect the aorta to pulmonary arteries. 
Arteriogenesis is like angiogenesis but refers to increasing the size in the diameter of 
existing arteries rather than the formation of new vessels entirely. Furthermore, the same 
study found that, eNOS knockout mice were not able to upregulate between 40-44 genes 
related to the cell cycle and could result in altered cell cycle progression (28). In other 
studies, transfer of the NOS 3 gene into vascular smooth muscle and human embryonic 
kidney cells was shown to inhibit cellular proliferation in both types of cells (12, 29). 
Ultimately, there is limited data available in the literature that directly measures the impact 
Table 2: Summary of the phosphorylation sites of eNOS and the resulting 
difference in NO output by residue type 
Residue Type: Residue 
Number: 
Activating/Inhibiting Reference 
Serine 114 Inhibiting (in vivo) 22-23 
600 Inhibiting (in vitro) 24 
615 Activating 19 
633 Activating 20 
1177 Activating 17-18 
Threonine 495 Inhibiting 21 
Tyrosine 81 Activating 26 
657 Inhibiting 26 
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of eNOS on cell cycle progression, further research is necessary to establish the nature of 
the linkage.  
There is considerable evidence that suggests eNOS may be actively regulated as the 
cell cycle progresses as part of global cellular mechanisms of regulation like 
phosphorylation. Two separate research groups have shown that eNOS is phosphorylated 
by CDK 1 and CDK 5 at ser114 (30-31). Phosphorylation of ser114 caused lowered nitrite 
production in SH-SY5Y cells transfected with both eNOS and CDK5/p35 (30). 
Additionally, CDKs 1, 2, and 5 were shown to phosphorylate ser114 in vitro and treatment 
with roscovitine, a CDK 1, 2, and 5 inhibitor prevented phosphorylation in vivo (31) This 
opens the possibility that eNOS may be regulated through CDKs. Another study has shown 
that VEGF mediated ser1177 phosphorylation is linked to vein formation in embryonic 
endothelial cells and regulates the formation of blood vessels (32). Besides 
phosphorylation, eNOS is regulated through interactions with other proteins like 
calmodulin. Another protein that interacts directly with eNOS is NOS interacting protein 
(NOSIP). NOSIP has been shown to interact with eNOS in a cell cycle dependent 
mechanism and is a nuclear ubiquitin ligase that is released to the cytoplasm as part of late 
cell cycle (33). Specifically, eNOS was shown to be downregulated during G2 phase 
through NOSIP-mediated subcellular localization of eNOS to the cellular cytoskeleton. 
Additionally, the activity of eNOS is lower in G2 compared to G1, this is reversed when 
NOSIP is knocked down by siRNA (33) Taken together this data opens the possibility that 
eNOS may be actively regulated during the cell cycle, specifically through an 
ubiquitination event that is cell cycle dependent. In this study, we present data that supports 
a connection between the cell cycle and eNOS. We have found that eNOS is increasingly 
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phosphorylated at ser600 during mitosis in human microvascular endothelial cells using 





CHAPTER 2 – EXPERIMENTAL 
Structure-based Sequence Alignment 
Materials 
 eNOS sequences were collected from the Swiss UniProt database manually.  
Sequences were aligned using the MUSCLE algorithm in Jalview 2.10.5. Jalview and 
Microsoft Word were used to analyze aligned eNOS sequences. A threaded model of the 
unstructured region of eNOS was made using Swiss-Model. The model was analyzed and 
refined in PyMol 2.3.2. 
Methods 
 eNOS protein sequences were collected using the “Add to basket” feature on the 
Swiss UniProt website following a blast query using the protein sequence of human eNOS. 
Sequences were only selected if more than 70% sequence homology was observed. 
Sequences were then compared to nNOS and iNOS and excluded if the PDZ domain and 
autoinhibitory loop matched nNOS or if no autoinhibitory loop was present. This resulted 
in a collection of 84 eNOS protein sequences from a variety of chordate species, primarily 
mammalian but also including some reptiles. It is worth noting that if this study is repeated, 
additional nonmammalian sequences should be collected. The collected sequences were 
downloaded in FASTA format and imported into Jalview and aligned using the MUSCLE 
alignment preset. The rendered sequence alignment was then truncated from the full length 
eNOS to only include the alignment region that matches with amino acid residues 566-674 
of human eNOS which includes the autoinhibitory loop. This region was then blasted on 
the Swiss UniProt website to determine a protein of high homology and resolved structure. 
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Based on this query, the human iNOS reductase and calmodulin complex flavodoxin-like 
domain was found (PDB 3HR4 (35)). The human eNOS flavodoxin-like domain from 
amino acid residue 520 to 703 was then queried into the Swiss-Model using 3HR4 as a 
template to create a threaded model of the autoinhibitory loop (AIL) of eNOS. The model 
of the AIL was then opened in PyMol and aligned to the flavodoxin-like domain of iNOS 
from 3HR4. Regions of structural homology in the model that correspond to the structure 
from 3HR4 were rendered in color and regions of unknown structure, mainly encompassing 
the autoinhibitory loop, were left gray. Using the sequence alignment, outliers were 
removed that maintained low homology in the AIL, and regions of structural homology 
were color coded to match the model in Microsoft Word.  
Cell Culture 
Materials 
 HMEC-1 cells (CRL-3243) were purchased from the American type culture 
collection (ATCC). MCDB 131 and hydrocortisone were purchased from Sigma-Aldrich. 
Epidermal growth factor (EGF), L-glutamine, and trypsin were purchased from Genesee 
scientific. Fetal bovine serum (FBS; E17063) was purchased from Atlanta Biologicals.  
Methods 
 Human microvascular endothelial cells (HMEC-1) were cultured as directed by the 
ATCC in MCDB 131 media with 10% FBS, 10 ng/mL epidermal growth factor, 1 μg/mL 
hydrocortisone, and 10 mM glutamine. Fully supplemented media is referred to as 
complete media. The cells were grown at 37 degrees C in a humidified environment with 
5% CO2 and passaged once 80-90% confluency was reached. Experiments used cells 
between passages 4-13 and were seeded into vessels dependent upon the experiment being 
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done – see the subsections for each method to determine what vessel was used and how it 
was seeded.  
 For maintenance passages in a T75 flask, media was aspirated, and cells were 
washed once for 45-60 seconds with 2 mL of trypsin which was then aspirated out of the 
flask. The cells were then trypsinized off the surface with 3 mL of trypsin incubated for 5 
minutes at 37 degrees C. It is worth noting that HMEC cells tightly adhere to surfaces so 
additional time may be required to remove all the cells from the surface. The trypsin was 
quenched with 1:1 ratio of complete media to trypsin. Then a portion of the quenched 
solution of trypsin and cells was moved into a T75 flask, at a dilution appropriate for the 
density of cells in the flask and the density desired. For example, consider a 1:3 dilution, 2 
mL of the cells in a trypsin/media mixture were added to 10 mL of complete media which 
was then placed into a T75 flask for a total volume of 12 mL. For experiment use, all of 
the steps are repeated, however instead of moving the quenched solution into a flask, a 
sample was collected, and the cells were counted before diluting the cells to the desired 
number and volume prior to placement into the experiment specific vessel. 
G2/M cell cycle synchronization 
Materials 
 RO-3306 was purchased as a 10 mM stock in DMSO from MedChemExpress.  
Methods 
 Cells were synchronized at the G2/M barrier using a CDK 1 inhibitor, RO-3306. 
The inhibitor was added to a final concentration of 5 μM to adherent cells in experiment 
specific vessels from a 10 mM stock solution prepared in DMSO (Med Chem Express). 
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The inhibitor treatment lasted 20 hours, then cells were washed once with unsupplemented 
MCDB 131 then complete media was added to initiate the time course. The amount of 
media added was dependent on the experimental method being used. The washout of the 
RO-3306 releases the cells from the G2/M barrier resulting in elevated populations of 
mitotic cells. It is worth noting that before use of this inhibitor, serum starvation was 
attempted to synchronize cells, however, the HMECs are hardier than anticipated and a 20 
hour serum starvation was not enough to arrest cells in G0. Therefore, if serum starvation 
is used in the future, a minimum of 24 hours, preferably 48 hours should be utilized. 
Immunofluorescence 
Materials 
 Lab-Tek 16-well Chamber Slide and coverslips (178599 and 171080) were 
purchased from ThermoScientific. PBS supplemented with calcium and magnesium (25-
508CB) was purchased from Genesee Scientific. 20% PFA (15713) was purchased from 
Electron Microscopy Sciences. Horse serum was purchased from Atlanta Biologicals. See 
appendix for primary and secondary antibodies and dilutions of antibodies used. 
Methods 
 HMEC-1 cells were collected as previously described and seeded into 16-well 
chamber slides at a density of 0.5 x 104 in 100 μL of media. After experimental treatment, 
cells were fixed with 4% PFA in PBS for 15 minutes at room temperature. Cells were then 
washed with 100 μL of PBS per well three times, then simultaneously blocked and 
permeabilized with 5% horse serum and 0.3% Triton x-100 respectively in PBS. All 
primary antibody staining was done overnight at 4°C with antibody specific dilutions – 
listed in the appendix – prepared in blocking buffer (5% horse serum, 0.3% Triton X-100, 
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and 0.01% sodium azide in PBS). After primary staining, cells were washed three times 
with 100 μL of blocking buffer per well. Then secondary antibody staining was done at 
room temperature for 45 minutes with manufacture recommended dilutions – also listed in 
the appendix – prepared in blocking buffer. Cells were washed two times with blocking 
buffer. Then nuclei were stained with DAPI in PBS, then cells were rinsed with PBS. The 
wells on the chamber slide system were then removed with brute force and the underlying 
silicon gasket was carefully lifted using fine tipped forceps. Once the gasket was removed, 
the slide was rinsed in PBS once, then mounted with Vectashield H-1000. Slides were 
imaged on a Zeiss LSM 700 confocal microscope. Images were processed and analyzed 
using Zeiss Zen Black and Blue software. 
Flow Cytometry 
Materials 
 Sterile 5-mL polypropylene tubes (21-125) were purchased from Genesee 
Scientific. RNase A (120-91-021) was purchased from Invitrogen. Bovine serum albumin 
(BSA) was purchased from Fisher Scientific. 
Methods 
 HMEC-1 cells were seeded into experiment specific containers with experiment 
specific seeding densities. Depending on the experiment, the cells were or were not treated 
with RO-3306. Following the treatment or lack of treatment, cells were trypsinized 
following the same protocol as for passaging cells with the alteration of including 3% BSA 
in PBS for quenching the trypsin instead of complete media. The cells were then spun down 
at 200xG for 5 minutes, then the quenching solution was aspirated and 1% PFA in PBS 
was added to fix the cells in suspension. The cells were fixed for 15 minutes at room 
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temperature, then the cells were washed with 2 mL of PBS, spun down at 200xG for 5 
minutes, and then supernatant was collected into PFA waste. The cells were then blocked, 
permeabilized, and RNase treated for 30 minutes with 3% BSA, 0.1% Triton X-100, and 
100 μg/mL of RNase A in PBS. The cells were then filtered through a 30 μm mesh and 
counted, cells were then resuspended to 10E6 cells/mL in 3% BSA in PBS. Then, 300 μL 
of cells were aliquoted into 5-mL sterile cell culture tubes – ensuring that an unstained and 
single stain samples were also collected – see the table below for an example of how cells 
were divided for an experiment. The ser600 phosphospecific antibody primary was diluted 
in 3% BSA in PBS and added to the cells to a final dilution of 1:200 for primary staining. 
The eNOS-Alexa Fluor 647 conjugated primary was used as the manufacturer specified, 
20 μL / 100,000 cells. The primary was incubated for 30 minutes at room temperature. The 
cells were then washed by centrifugation with 4 mL of ice cold 0.5% BSA in PBS at 200xG 
for 5 minutes. The secondary staining was also done following manufacturer recommended 
dilutions with the same conditions as the primary staining. Propidium iodide was added to 
50 μg/mL final concentration to the secondary staining solution to simultaneously stain 
DNA and detect the primary antibody with a labeled secondary antibody. Finally, excess 
antibody and PI was washed out by centrifugation with the same conditions as for washing 
out the primary. The cells were resuspended in approximately 250 μL of PBS and samples 
were then run through a BD Accuri C6 flow cytometer with a fast flow rate with an 






 Gel electrophoresis and western transfer reagents were made in house. Mini protean 
TGX 8-16% gradient gels (Ref #: 456-1103), gel electrophoresis equipment, and western 
transfer equipment were purchased from Bio-Rad. Prometheus OneBlock Western-FL 
Blocking Buffer was purchased from Gennesee Scientific. TBST was made in house. 
Protease inhibitor cocktail and Pierce 660 nm protein assay reagent were purchased from 
ThermoScientific. See appendix for primary antibodies and dilutions of antibodies used.  
Methods 
 Approximately 7 x 105 HMEC-1 cells were seeded into 8 10 cm2 dishes and allowed 
to grow for 1.5 days before treatment with RO-3306 or DMSO for 20 hours. After 
treatment, the RO-3306 inhibitor was washed out of the 8 dishes of cells, each with slightly 
differing conditions – vehicle (DMSO), 0 mins, 15 mins, 30 mins, 45 mins, 60 mins, 90 
mins, and 120 mins after washout. This allows for a time course with time points that 
captures cells as they initiate and progress through mitosis. Cells were harvested by lifting 
with a cell lifter into ice cold lysis buffer (150 mM NaCl, 50 mM Tris-HCl (pH 7.4 at 4C), 
1.5 mM MgCl2, 10% glycerol, 1% Igepal, and 0.5% Triton X-100) supplemented with 1X 
protease inhibitor cocktail, 1 μM micro-cysteine, and 2 μM sodium vanadate. Lysates were 
flash frozen with a splash of liquid nitrogen and placed into the -80C for storage until 
sample preparation. For sample preparation, lysates were spun down at 18,000xG, the 
supernatant was collected, and the pellet was discarded. A Pierce 660 nm protein assay was 
done using samples of the supernatants as specified by the manufacture for a microplate 
assay. Once the protein concentration was determined, samples were prepared by adding 
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4X sample buffer with 100 mM DTT to a final concentration of 1X and 25 mM DTT. 
Samples were then boiled for 5 minutes while a calculation was performed to determine 
the volume of each sample necessary to load 15 μg of protein onto a 10% SDS gel. Gels 
were run at 30 mA until the dye front had run off the gel. Proteins were then transferred 
onto PVDF membrane using the tank method for western transfers. The condition for 
transfers was 100 V constant for 60 minutes at 4C. Blots were blocked for 1 hour in 
OneBlock. Primary antibodies were diluted in OneBlock to manufacturer recommended 
specifications – see appendix for specific dilutions used – and incubated overnight at 4C. 
Blots were washed 5 times total – 1 fill and dump, 3 5-minute washes, and 1 fill and dump 
in that order – with TBST. Secondary was diluted in OneBlock to a final dilution of 
1:15000 and blots were incubated for 45 minutes at room temperature. The blot was washed 
the same as after primary antibody staining and scanned on a Licor Odyssey and data was 




CHAPTER 3 – RESULTS 
The autoinhibitory loop is highly conserved 
 Comparison of primary eNOS sequences from 50 different species shows that the 
autoinhibitory loop (AIL) is highly conserved across the species studied (figure 3). The 
sequence alignment is highlighted based on homology to Homo sapien eNOS. The 
mammalian sequences are conserved throughout the entire AIL (shown in grey in figure 2) 
with the most significant variation existing at the val616, which is conservatively substituted 
for an isoleucine in some mammals including humans. This conservative mutation likely 
stems from a base substitution event at the first base in the codons ATT, ATC, or ATA for 
valine to GTX for isoleucine where X is any base. When comparing eNOS orthologs from 
closely related taxonomic orders, we observe some minor divergences. Specifically, serine 
residues substituted for threonine residues and lysine residues for arginine residues occur, 
but these alterations are unlikely to change the overall structure or activity of the protein. 
Only one organism is shown per genus, also some exceptions were encountered like Ursus 
americanus where insertion or deletion events have significantly altered the AIL, but these 
were removed from the final sequence alignment.  
Phosphorylation sites on eNOS are conserved 
 Many of the phosphorylation sites that influence activity changes in eNOS are 
highly conserved throughout mammalian eNOS orthologs. These sites include tyr81, thr495, 
ser615, ser633, tyr657, and ser1177, where the substrate specificity is maintained upstream and 
downstream of the phosphorylation site. Ser114 is conserved in mammals but some variation 
occurs in the substrate specificity sequence. In primates, the amino acid after ser114 is 
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pro115, but this proline is replaced with a glutamine in other closely related mammalian 
orders which would likely change the kinase capable of phosphorylating this site to a kinase 
that is not proline directed. Ser615, ser633, and tyr657 are indicated by an asterisk on figure 2. 
Phosphorylation sites significantly distant (tyr81, ser114, thr495, and ser1177) from the AIL are 
not shown in figure 2. Ser600 is highly conserved in mammals and marsupials, but not 
conserved in eNOS orthologs from more divergent taxonomic orders like birds, 
amphibians, and reptiles (shown without ser600 in the lower portion of figure 2). This 
suggests that ser600 may have some evolutionary significance in mammalian eNOS 
Figure 2. Alignment of human nNOS, human iNOS, and chordate eNOS sequences highlighting 
structural similarities. Colored residues represent conserved structural elements and are highlighted 
when identical to human eNOS. Highlighted colors correspond to secondary structural elements found in 
the structural model of the eNOS flavodoxin-like domain shown in figure 4. Arrows indicate beta strands 
and cylinders indicate alpha helixes. Conserved phosphorylation sites are indicated by an asterisk. Ser600 
is highlighted in purple and indicated with a “?” on the sequence. The autoinhibitory loop is highlighted 






orthologs. This observation is supported by the phylogenetic tree of NOS enzymes 
published by Andreakis et al (34). Specifically, at the branch point between avian eNOS 
orthologs and the most common ancestral eNOS ortholog between mammals and 
marsupials. However, as this information comes from a limited dataset, the study should 
ultimately be independently repeated with additional data. 
 Structural elements of the autoinhibitory loop are conserved. 
 Structurally, the AIL has not been elucidated, likely due to flexibility in that region. 
In all the crystal structures available for NOS enzymes, this region did not provide electron 
density and may be a flexible region of the protein with inconsistent positioning in the 
crystals. The region is highly conserved across mammalia and reptilia. Due to the lack of 
structural data of the AIL, a threaded model of that loop and the surrounding domain was 
made using the crystal structure of the flavodoxin-like domain of iNOS found in PDB 
3HR4 shown in figure 3. From this model and a comparison of the sequences (figure 2), 
multiple beta sheets and alpha helixes were found to be conserved (highlighted in cyan, 
green, yellow, and red in figure 1 to match the colored regions of the model in figure 3). 
The AIL had virtually no structurally resolved information, the closest comes from rat 
nNOS reductase domain (PDB 1TLL (36)), but only a few amino acids within the rat nNOS 
AIL had structural information associated with them resulting in a small resolved helix. 
However, this helix may not be present in eNOS due to differences in the primary structure 
around that region. Comparing the primary structure within the AIL between nNOS and 
eNOS, it appears that eNOS has more hydrophobic residues (leu622, val623, and trp626) 
which could be contributing to a small hydrophobic pocket that is absent in the nNOS. The 
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amino acid residues at these positions in nNOS are small, polar amino acids (ser822, gln823, 
and ser825). One explanation is that eNOS maintains a small hydrophobic pocket which is 
absent in at least the reported structure of 1TLL of nNOS. Another explanation could be 
differences in binding partners for nNOS and eNOS, where the eNOS AIL uses 
hydrophobic interactions with its binding partners and whereas the nNOS AIL uses charged 
Figure 3. Structural model of the flavodoxin-like domain of eNOS. The model was created using 
Swiss-model with the structure of human iNOS bound to calmodulin used as the template (PDB 3HR4). 
The colored regions represent areas of high structural homology, whereas the grey region is of unknown 
structure and encapsulates the autoinhibitory loop of eNOS. Ser600 is shown in purple. Ser615 and ser633 
are shown in pink. The proposed MAPK binding domain is shown in yellow in the AIL. Tyr657 is shown 










interactions with its binding partners. Overall, conclusions are difficult to make about the 
structural nature of the AIL due to the lack of structural data in that region. However, the 
distance of ser600 from the FMN in the structure, makes it is unlikely that phosphorylation 
perturbs the electron transport occurring near the FMN and therefore as our most current 
data suggests (supplemental figure 1), ser600 phosphorylation may not influence nitric oxide 
production directly. However, phosphorylation here could influence eNOS binding 
partners due to the hydrophobic amino acid residues located near ser600 in the model. With 
regards to the eNOS dimer, ser600 is positioned within the FMN binding region of the eNOS 
monomer. This is not associated with the dimerization interface in either the oxygenase or 
reductase domain of the eNOS monomer (37). 
Ser600 phosphorylation is modulated in a small subpopulation of late cell cycle HMEC cells 
 The physiological significance of phosphorylation of eNOS at ser600 has not been 
characterized. Only one reference exists on this site from our lab. To better understand the 
importance of this highly conserved site in mammals, we used immunofluorescence to 
observe P-ser600 with a phosphospecific antibody in cycling endothelial cells (figure 4). We 
found that only a small subpopulation of cells showed significant staining with this 
antibody. A pattern of the staining was that only cells partially released from the growth 
surface and cells that were rounded up showed increased staining (figure 4A). This led us 
to believe that either apoptotic or mitotic cells were showing P-ser600. Based on the DNA 
morphology, it initially appeared that cells that have heightened phosphorylation at ser600 
have condensed DNA and are mitotic as two cells are in metaphase and one cell is in 
anaphase (figure 4A). To follow up on this, flow cytometry was deployed to assess DNA 
density and to characterize the cell cycle of P-ser600 elevated cells (figure 4B). We observed 
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that P-ser600 was found in cells that primarily have N=4 DNA. This indicated that cells 
positive for ser600 phosphorylation were at G2/M phase. Comparatively, cells that show 
basal staining for P-ser600 have cells at N=2, 2<N<4, and N=4 DNA indicating that G1, S, 
and G2/M phase cells are observed (figure 4B). Additionally, no DNA fragmentation was 
observed in P-ser600 elevated or basal cells leading us to surmise that apoptotic mechanisms 
are not correlated with the phosphorylation of ser600. Taken together with the DNA staining 
in immunofluorescence, we believe that ser600 phosphorylation is modulated during mitosis 
in microvasculature, making our lab the first to link this phosphorylation site to other 
regulatory processes in the endothelium. 
Figure 4. eNOS ser600 phosphorylation is only observed in a subpopulation of cells. Representative 
image of indirect immunofluorescence (A) and indirect flow cytometry (B) demonstrating that ser600 
phosphorylation is observed at high levels a small subpopulation of cells. Observations are representative 










Figure 5. eNOS ser600 phosphorylation is elevated with mitosis. Representative data of indirect flow 
cytometry demonstrating that treatment with 5 μM RO-3306 results in reversible G2/M synchronization 
(A) and that Ser600 is elevated by treatment with RO-3306 and washout of inhibitor (B). Representative 
image of indirect immunofluorescence showing that with washout of 5 μM RO-3306, a G2/M inhibitor, 
the population of mitotic cells increases as well as ser600 phosphorylation, scale bar represents 50 μm (C); 
a magnified image of two cells in metaphase is shown, scale bar represents 20 μm (D). Observations are 







Ser600 phosphorylation is elevated in mitotic endothelial cells 
 Given that ser600 phosphorylation was observed in cells that appear to be in late cell 
cycle or in G2/M phase based on the DNA content, we further investigated the point of 
modulation for P-ser600 in the cell cycle. To investigate this, we deployed a reversible CDK 
1 inhibitor that arrests at the G2/M barrier – RO-3306. Upon washout of the inhibitor, cells 
rapidly begin mitosis (figure 5A).  We observed an increase in P-ser600 after RO-3306 
treatment (figure 5B). Using immunofluorescence and staining with anti-histone H3 ser28 
phosphorylation – a mitotic indicator – we observed strong concomitant staining between 
the two antibodies (figure 5C). Magnification of the staining is shown in figure 5D. This is 
reflective of P-ser600 being modulated during the cell cycle and confirms that P-ser600 is 
modulated in specific circumstances during the start of mitosis and not during G2 phase. 
Additionally, flow cytometry following 45 minutes after the RO-3306 washout showed 
roughly 6 times greater proportion of cells P-ser600 elevated compared to the vehicle 
control. Suggesting P-ser600 is modulated by a kinase that is activated during early mitosis.  
eNOS levels do not significantly change throughout the cell cycle 
 To ensure that the elevation in P-ser600 is not from changing levels of eNOS protein, 
we employed additional immunofluorescence and flow cytometry. Using an anti-eNOS 
monoclonal antibody in immunofluorescence, we found that eNOS staining is consistently 
observed in cycling cells (figure 6A). To analyze a larger number of cells and to assess the 
cell cycle, flow cytometry was used to observe eNOS while co-staining with propidium 
iodide to measure DNA content. This showed us that eNOS positive cells were found at all 
points of the cell cycle (figure 6B). When comparing DNA content to eNOS staining, little 
difference is observed throughout the cell cycle, with eNOS levels staying at a relatively 
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consistent level (figure 6C). Taken together, we believe that eNOS levels are remaining 
consistent throughout the cell cycle and the P-ser600 is not elevated due to an increase in 
eNOS protein.  
Proximity ligation assay verifies P-ser600 antibody specificity 
 To build on our previous publication (24) and further validate our P-ser600 antibody 
specificity to eNOS, we used an in-situ proximity ligation assay (PLA) kit from Millipore. 
This kit was adapted from a publication by Söderberg et al. (38). Simplified, this assay uses 
the principles immunofluorescence and rolling circle PCR. The immunofluorescence 
component of the assay used the same steps as normal immunofluorescence, but replaced 
fluorophore conjugated secondary antibodies with pseudo-secondary antibodies 
conjugated to DNA oligonucleotides to detect bound primary antibodies – in this case, the 
Figure 6. Total eNOS is observed throughout the entire cell cycle. Representative image of indirect 
immunofluorescence (A) and direct flow cytometry (B) demonstrating that eNOS is observed 
throughout the cell cycle. eNOS protein levels are also relatively consistent throughout the cell cycle 
when compared to PI staining (C). Observations are representative of three independent experiments. 










BD Biosciences eNOS monoclonal antibody and our P-ser600 antibody. The rolling circle 
PCR component used three things, additional DNA oligonucleotides to form a complete 
circular sequence of DNA, a ligase to ligate this circular DNA, and a polymerase to amplify 
the linear DNA conjugated to the antibody. Detection was accomplished using 
complimentary DNA oligonucleotides conjugated to fluorophores.  Signals using this PLA 
kit are only produced when primary antibodies are within 40 nm of each other. In our study, 
we observed little to no signal when no primary antibodies were used (figure 7A). 
However, when using PLA with an eNOS monoclonal antibody and our polyclonal P-ser600 
antibody, we observed punctate signals in the periphery of the cell (figure 7B). The 
punctate signals are in similar position in the cell as observed when staining with the P-
Figure 7. Proximity ligation assay of an eNOS monoclonal antibody and the P-ser600 antibody. 
Proximity ligation assay results using a mouse monoclonal eNOS antibody and our rabbit polyclonal 
eNOS ser-600 phosphorylation antibody, without primary antibodies no signal is observed (A) whereas 







ser600 antibody alone – on the periphery of the cell. This data supports the specificity of our 
antibody and helps validate our previous observations with this antibody. 
eNOS phosphorylated at ser600 is shifted by 10 kD on SDS-PAGE 
 Given that we can elevate the amount of P-ser600 observed by synchronizing cells 
at the G2/M barrier, we wanted to collect semi-quantitative data using western blot 
analysis. We confirmed our finding that eNOS phosphorylated at ser600 is elevated around 
30-60 minutes after entrance into mitosis, and observed, under our western conditions, that 
the P-ser600 antibody reacts with a band that is shifted by 10 kD when compared to eNOS 
reactivity using several eNOS antibodies. We observe reactivity of the mouse monoclonal 
eNOS antibody at approximately 140 kD whereas the P-ser600 antibody is reacting roughly 
10 kD higher at approximately 150 kD (figure 8). It is worth noting that the eNOS antibody 
does not also react with the 150 kD band unless we significantly increase the input. This 
suggests that an amount of eNOS that can react with eNOS antibody is not present in the 
heavier band and likely means that a smaller amount of eNOS is present at the heavier 
band. Interestingly, reaction to a P-ser1177 antibody, which has an epitope that could overlap 
Figure 8. eNOS P-ser600 is shifted by 10 kD on western blots. Western blot analysis shows that eNOS 
P-ser600 is shifted by roughly 10 kD heavier than eNOS. Comparatively, eNOS modified by other 







with the eNOS antibody used in this blot. Together, this suggests that P-ser600 may be co-
posttranslationally modified with a modification of roughly 10 kD.  
Other eNOS phosphorylation sites are not changing significantly after RO-3306 washout 
 Using the same methodology to assess P-ser600 with western blotting, we 
investigated other commonly studied phosphorylation sites on eNOS. We found that 
phosphorylation at ser1177 is slightly elevated in cells at 15-120 minutes after RO-3306 
washout when compared to the vehicle control and 0-minute (G2/M block intact) time 
point. However, when compared to the degree of modulation of P-ser600, the change in P-
ser1177 and P- ser635 is minimally elevated compared to the vehicle treated cells. 
Additionally, other sites like, ser114 and thr495 do not seem to be changing throughout the 
time course (figure 9). It is worth noting that we did not explore phosphorylation of tyr 
residues with our western blots which may be worth a brief investigation. 
Figure 9. Western blot analysis of phosphorylation of other eNOS sites. Representative western blot 
of two independent experiments showing phosphorylation status of multiple eNOS phosphorylation sites 









MAPK activation does not correspond to the increase in eNOS P-ser600 
 Previous data from our lab showed that eNOS can be phosphorylated by MAPKs. 
Specifically, eNOS is phosphorylated by ERK, JNK, and p38. Where JNK phosphorylates 
at ser114, ERK phosphorylates at ser600, and p38 phosphorylates both sites (supplemental 
figure 2). It is worth noting that MAPK phosphorylation was used as a measure of kinase 
activity and that ideally, a substrate should be looked at to ensure activity. All three MAPKs 
seem to be phosphorylated significantly at 15 minutes into the washout when compared to 
the vehicle or 0-minute time point (figure 10). At first glance, this seems to match up with 
the increase in eNOS P-ser600, but this does not appear to be entirely the case. P38 
phosphorylation decreases by 30 minutes into the time course which makes it unlikely to 
be the cause of peak P-ser600 at around 45 minutes (figure 10). JNK is unable to 
phosphorylate eNOS at ser600 in vitro (supplemental figure 2). ERK maintains the 
activation phosphorylation sites for the entire time frame which makes ERK more likely to 
enhance P-ser600, however, the ERK phosphorylation lasts significantly longer than ser600 




Figure 10. Western blot analysis of MAPKs. Representative western blot of two independent 










CHAPTER 4 – DISCUSSION 
 In order to assess the possible significance of eNOS ser600 phosphorylation, we 
created a multiple sequence alignment to verify that more than just humans and cows have 
this phosphorylation site. The eNOS protein sequence alignment shows us that there is high 
conservation throughout most of the primary and secondary protein structure of eNOS 
(figure 1). We also found that all phosphorylation sites that influence activity are conserved 
across taxonomical classes in our data set. Our data matches observations in a detailed 
study on the phylogeny of NOS enzymes by Andreakis et al. However, it is still worth 
mentioning that our data set is limited to a blast search using the protein sequence of eNOS.  
Our study found that ser600 occurs exclusively in mammals and marsupials in our 
data set. This suggests that as part of the evolutionary differentiation from reptiles and aves, 
this site appeared in mammals. One possible explanation for the appearance of this site 
may correspond with the branch that distinguishes cold-blooded animals from warm-
blooded animals. Our data suggests that ser600 may have been a more recent mutation in 
eNOS which aligns with the phylogenetic analysis of NOS enzymes by Andreakis et al 
(34). That study identifies eNOS as the last NOS enzyme to appear in organisms. However, 
as there is limited data in the literature on this site in other species outside of cows, further 
work is necessary before significant conclusions can be made on the evolutionary 
significance of ser600.  
Using the same sequence alignment, we found that all phosphorylation sites that 
alter NO production by eNOS were conserved in our data set. However, ser114 and ser600 
were only found in sequences from warm blooded animals in our study. We believe that 
these sites do not directly influence NO production of eNOS by perturbing electron 
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transport, but rather, influence eNOS binding partners which may contribute to the 
ambiguity in activity differences observed in the literature (39). Another observation stems 
from a conserved phosphorylation site between tyr657 on eNOS and tyr895 on nNOS. 
Phosphorylation at this site has inverse effects between the two NOS enzymes where on 
eNOS it inhibits activity, but on nNOS it enhances activity. This likely results from other 
differences found on the nearby AIL. In nNOS, the region has fewer hydrophobic residues 
than eNOS. Additionally, there is a WRKRRK portion on eNOS this is absent from nNOS. 
We have proposed that this motif is a MAPK binding site (24). Therefore, eNOS may be 
more heavily regulated by MAPKs via the AIL. However, in order to make strong 
conclusions, a structural model of the AIL is necessary. While parts of eNOS and other 
NOSs have resolved structural information, the AIL has not been elucidated for both 
enzymes, therefore it is difficult to attribute differences in activity solely on differences in 
the primary structure.  
The AIL has not been fully elucidated structurally. However, due to the partial 
homology in primary sequence and high conservation of structural elements between NOS 
enzyme structures we were able to create a threaded model using the structure of human 
iNOS bound to calmodulin (PDB 3HR4). Specifically, we used the flavodoxin-like domain 
as our template for the model because of the high structural conservation between eNOS 
and iNOS which includes multiple alpha helices and beta strands that can act as anchor 
points. Three sites found on the AIL have been published to directly influence eNOS 
activity in the literature ser615, ser633, and tyr657 (none shown in figure 2). Of these sites, 
tyr657 has been structurally resolved in multiple reported NOS structures and is found in 
the FMN binding site which explains how phosphorylation could sterically hinder FMN 
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binding and cause the reported inhibitory effect (40). The other serine sites known to 
influence eNOS activity are more likely to be near the FMN bound to eNOS acting to 
enhance electron transport. However, since these sites are not fully elucidated structurally, 
exact positions in the structure of eNOS are not entirely known. One site that is also found 
in the AIL is ser600, this site is near the base of a helix that is completely resolved and 
involved in the FMN binding domain of the flavodoxin-like domain of eNOS (shown in 
purple in figure 2). This makes it more likely that ser600 is more not influencing activity 
due to the distance from the FMN. However, phosphorylation at ser600 could influence 
eNOS binding partners resulting in an indirect activity changes or changes in subcellular 
localization.  
In testing our phosphospecific ser600 antibody, we observed a significantly elevated 
level of staining in rounded cells that were partially detached from the slide. At first, we 
thought this staining was identifying cells undergoing apoptosis, but after closer inspection, 
it appeared that the DNA was not fragmenting but rather condensing like at the start of 
mitosis. This was verified using flow cytometry and looking at DNA density where we 
observe a small population of P-ser600 elevated cells that corresponds to the percentage of 
cells that could be in mitosis in an asynchronous population. The DNA staining matched 
with N=4 DNA suggesting late cell cycle cells are P-ser600 elevated (figure 3). Additionally, 
we were able to increase the population of P-ser600 using a CDK 1 inhibitor – RO-3306 – 
to synchronize cells at the G2/M checkpoint (figure 4). This inhibitor is reversible and 
therefore should minimally interact with other kinases, but nonetheless it has been reported 
to interact with PKC gamma and serum/glucocorticoid-regulated kinase (SGK) with a Ki 
(nM) of 318 and 497 respectively. Other kinases that have been shown to phosphorylate 
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eNOS such as, ERK, PKA, and AKT had an approximately 2000 nM Ki or greater (41). 
Ultimately, we believe that the inhibitor itself is not directly impacting levels P-ser600 and 
is acting as a cell synchronization agent in our conditions. Therefore, by using cell 
synchronization and immunofluorescence costaining we observed that P-ser600 is elevated 
during mitosis. We further verified this direct link between P-ser600 and mitosis by 
detecting histone H3 ser28 phosphorylation which is a mitotic indicator (42). Additionally, 
DNA density staining also supports our interpretation. Ultimately, our data supports the 
notation that P-ser600 is enhanced during mitosis. 
In order to ensure that changes in P-ser600 are not from changing eNOS levels, we 
employed both immunofluorescence and flow cytometry. This showed that asynchronous 
cells maintain a similar amount of eNOS (figure 5) throughout the cell cycle. When 
comparing our data with the literature, we found that eNOS does not significantly change 
throughout the cell cycle (43). Therefore, we believe that P-ser600 is not elevated due rising 
eNOS levels. However, because our study relies on an antibody to P-ser600 with limited 
reported data, we wanted to verify specificity of the antibody. We did this by using a 
proximity ligation assay which produces signal only if two antibodies are within 40 nm. 
This highly specific assay was employed with a mouse monoclonal antibody to eNOS and 
our rabbit anti-P-ser600 antibody. This produced a similar signal to what is observed with 
immunostaining of P-ser600, therefore we conclude that our antibody is specific to eNOS 
(figure 6). Additionally, we immunoprecipitated with the P-ser600 antibody, collected the 
main band around 150 kD, and submitted for mass spectrometry. After a trypsin digestion, 
we observed fragments of eNOS protein in our sample (supplemental figure 4). We have 
also previously reported that the antibody signal is ablated when treating lysates with 
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lambda phosphatase and antibody signal is elevated when eNOS is incubated with ERK 
(24). Taken together, this suggests that our antibody is specific to eNOS that is 
phosphorylated at ser600. 
 Our study also found significant elevation in P-ser600 through western blotting by 
collecting cell lysates different time points following release of the G2/M block by RO-
3306. Interestingly, eNOS that was phosphorylated at ser600 was shifted by 10 kD in our 
conditions (figure 7). We hypothesize that this shift is the result of some posttranslational 
modification that is approximately 10 kD. We also observe a slight, but nonetheless 
significant elevation in P-ser1177 (figure 8). Gentile et al. has observed that P-ser1177 is 
elevated in mouse embryonic endothelial cells when stimulated with VEGF as part of 
angiogenesis in embryonic development (32). Similarly, our data supports that dividing 
microvascular endothelial cells have an increase in P-ser1177. This is likely also associated 
with angiogenesis mechanisms for formation of new capillaries. However, when 
comparing our data with quercetin induced mitotic arrest of bovine aortic endothelial cells, 
we do not observe the same modulation in eNOS phosphorylation sites (44). Jackson et al. 
found that P-ser114 and P-ser615 are decreased with increasing amounts of mitotic arrest. 
Also, Jackson et al. found that P-ser1177 and P-thr495 were consistent regardless of degree 
of mitotic arrest. However, under our conditions, we observed consistent levels of P-ser114 
phosphorylation, decreasing P-thr495, and increasing P-ser1177. This raises the possibility 
that there may be significantly different mechanisms governing the regulation of eNOS 
phosphorylation between microvasculature and macrovasculature during cellular division.  
 We previously reported that ERK can phosphorylate eNOS at ser600 in vitro (24). 
Here we show that in situ phosphorylation of ser600 is likely not caused by a MAPK. We 
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found that elevation of P-ser600 does not correspond to elevations in MAPK activation 
phosphorylation (figure 9). We found that JNK is unable to phosphorylate at ser600 in vitro 
and is highly unlikely to phosphorylate in situ (supplemental figure 2). Additionally, we 
found that p38 can phosphorylate at ser600 but the phosphorylation of p38 in our time course 
does not correspond to changes in P-ser600. ERK was thought to be the physiological 
kinases responsible for P-ser600, but the EGF in the media stimulated cells for greater than 
2 hours, which does not correspond to the elevation in P-ser600. Together, this rules out 
JNK and p38 as the physiological kinase responsible for the phosphorylation in our 
conditions. Therefore, we suggest that an EGF independent mechanism of ERK activation 
may still be responsible for the elevated P-ser600, but further work is necessary before 
strong conclusions can be made. Additionally, we did in vitro kinase activity assays with 
eNOS and CDK 1/cyclin B, CDK 2/cyclin E, and CDK 5/p25. We found that CDK 2 and 
CDK 5 are both able to phosphorylate at ser600 (supplementary figure 3). Together this tells 
us that a CDK could be responsible for the phosphorylation event, but ultimately further 




CHAPTER 5 – CONCLUSIONS AND FUTURE DIRECTIONS 
 All together our study has found that ser600 phosphorylation is modulated during 
late cell cycle and at the start of mitosis. Additionally, this phosphorylation event is not 
attributed to an increase in overall eNOS protein levels. We were able to verify this through 
multiple experimental methods ranging from immunofluorescence, flow cytometry and 
western blotting. Additionally, we have verified that our P-ser600 antibody is specific to 
eNOS that is phosphorylated at ser600 which helps provide additional data to the limited 
data available on this antibody. We have attempted to also distinguish which kinases are 
responsible for the P-ser600. This resulted in ruling out p38 and JNK for the P-ser600 at the 
start of mitosis and found that ERK could be responsible in what would be hypothesized 
to be an EGFR independent mechanism, but ultimately further work is necessary to make 
stronger conclusions about ERK involvement in ser600 phosphorylation. Additionally, we 
found that eNOS is shifted by 10 kD on gels when it is phosphorylated at ser600 which 
suggests that another posttranslational modification on eNOS is occurring, one which 
causes this 10 kD shift. Even more interestingly, we found that eNOS phosphorylated at 
ser600 is found in a unique distribution pattern within cells, but this also needs additionally 
research before a stronger conclusion can be made. Taken together, we have presented data 
that shows that ser600 is phosphorylated in tissue culture and its modulation in a cell cycle 
dependent manner. This work should be replicated using animal models in order to fully 
understand the significance of ser600 in the context of the cardiovascular system. 
 One possible explanation for the role of ser600 phosphorylation physiologically 
could be through migration. Our lab had found that CDK 5 is capable of phosphorylating 
at ser600. Recently, Lampropoulou et al. found that CDK 5 is involved in endothelial cell 
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migration as part of pleiotrophin agonized mechanism. Pleiotrophin is a hypothesized 
angiogenic growth factor that is binds with strong affinity to heparin receptors (45). 
Together this suggests that a potential physiological roll for eNOS ser600 phosphorylation 
could be participation in migration. While ser600 phosphorylation directly does not seem to 
influence NO output, when coupled with phosphorylation by an activating kinase, protein 
kinase A (PKA), eNOS output is significantly greater than with PKA incubation alone (data 
not shown). Additionally, it appears that ser600 phosphorylation in immunofluorescence 
shows a unique staining pattern like what is observed when staining with intermediate 
filaments suggesting a cytoskeletal specific distribution. The cause of the distribution is 
unknown, but we believe that the phosphorylation at ser600 in conjunction with the 
additional modification resulting in the observed 10 kD shift on SDS-PAGE could together 
result in the unique staining. The increased NO output by eNOS could be the mechanism 
used to break down these cytoskeletal elements as part of the pleiotrophin induced CDK 5 
mediated endothelial cell migration observed by Lampropoulou (46). One way to test this 
would be by using the method described by Ni et al. to immortalize microvascular 
endothelial cells from mice. So long as the original eNOS promoter is not changed as part 
of the knockout, theoretically, we could introduce a plasmid with that promoter and the 
sequence of eNOS with mutations at residues of eNOS we are interested in without the 
worry of dealing with the wild type population of eNOS that would be present in simple 
transfection experiments with other endothelial cells. It would be interesting to investigate 
the role of ser600 on endothelial cell migration using this model system. Additionally, if the 
other posttranslational modification we believe is associated with ser600 phosphorylation is 
found to be a mono ubiquitin-like modification (approximately 8 kD and includes protein 
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like ubiquitin, small ubiquitin-like modifier (SUMO) proteins, or NEDD8), then we could 
theoretically mutate the lysine residue to a arginine residue which would be unable to be 
modified. This could result in different physiological changes, but we believe the most 
likely observation from this set of experiments would be a change in the subcellular 
distribution of ser600 phosphorylated eNOS from localization at intermediate filaments to a 
cytoplasmic distribution. Additionally, the physiological role of NO in migration could be 
perturbed and the rate of migration for cells without the lysine modification could be much 
slower as cytoskeletal intermediate filaments may not be broken down as efficiently as the 
wild type eNOS. This is one possible explanation for the role of ser600 phosphorylation, 
ultimately, a significant amount of work is necessary before stronger conclusions can be 
made. 
 One interesting route of investigation would be to look at differences in ser600 
phosphorylation between male-derived compared to female-derived endothelial cells. 
Recently, Cattaneo et al. identified that differences in eNOS expression and function 
between male-derived and female-derived endothelial cells (42). This group found that 
eNOS expression is twice as high in female endothelial cells compared to male endothelial 
cells. Additionally, they found that the mechanisms surrounding endothelial functions like 
migration was sex specific. For example, they observed that male endothelial cells use an 
eNOS independent and cellular proliferation-based mechanism for wound recovery 
whereas female endothelial cells use an eNOS dependent and cellular proliferation 
independent mechanism. To elaborate, female endothelial cells rely on eNOS to assist in 
recovering from wounding and do not simply just divide to fill the wounded area like male 
endothelial cells. As part of this mechanism, female endothelial cells get larger than male 
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endothelial cells. With the differences in wound recovery in mind, due to the mitotic nature 
of ser600 phosphorylation, we believe that male endothelial cells would express elevated 
levels of P-ser600 as part of wound recovery and this would not be observed in female 
endothelial cells due to the proliferation-independent mechanism governing wound 
recovery. This could be the result of differences in gene expression where the network of 
genes guiding wound healing are sex specific. However, if P-ser600 is also associated with 
a role in breaking down the cellular cytoskeleton, then elevation may also be observed in 
female endothelial cells as intermediate filaments are broken down with enhanced 
production of NO. Ultimately, over 6,500 protein-coding genes have been found to have 
differential expression in adults based on sex (47). This opens the possibility of sex-specific 
regulatory elements which could result in totally different regulation mechanisms between 
males and females. Ultimately, further research is necessary in order to determine the 
influence that sex-specific gene networks have on NOS regulation. 
 Another route of investigation could be on the regulatory differences between the 
microvasculature and macrovasculature. It is well established that the endothelial 
phenotype differs slightly based on the vascular bed the endothelial cells are associated 
with (48). Despite many physiologically similar functions, endothelial cells are different 
segmentally. For example, phenotypically, arterial endothelial cells are different than 
capillary endothelial cells which are different than venous endothelial cells. There are two 
major classes of endothelium, microvascular and macrovascular. There is ambiguity in the 
literature with regards to endothelial functional differences between these two types of 
endothelium where some researchers report finding an association between micro- and 
macrovasculature and others do not (49-51). This suggests that the underlying mechanism 
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may be organ specific and varies by disease. Additionally, it is important to note that the 
single layer of endothelium surrounds other organs besides the interior of blood vessels 
and is inherently difficult to isolate and study. However, this leaves open the possibility 
that endothelium associated with different organs may be regulated differentially. It would 
be worth studying the regulatory differences that result in the ambiguity in the literature 
regarding the functional association between microvasculature and macrovasculature. 
Specifically, it would be interesting in the context of phosphorylation regulation during 
mitotic events associated with wound recovery and angiogenesis. As well as, the role of 
eNOS ser600 phosphorylation in these conditions. Ultimately, due to limited amount of data 
available in the literature with regards to ser600, significantly more research is necessary 
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Supplementary Figure 1  
Supplementary Figure 2 
 
 
Phosphorylation of eNOS at ser600 and ser114 does not significantly alter NO production in vitro. 
Phosphorylation of eNOS with a kinase that phosphorylates at activating serine sites results in significant 
enhancement of NO production (A). Phosphorylation at ser600 by ERK and phosphorylation at ser114 and 








MAPKs differentially phosphorylate eNOS ser-pro sites. ERK can phosphorylate eNOS at ser600 but 
not at ser114. JNK can phosphorylate at ser114 but not at ser600. P38 can phosphorylate at both ser600 and 










Supplementary Figure 3 
 
  
In vitro kinase assay with CDK 1/cyclin B, CDK 2/cyclin E, and CDK 5/p25. 2.2uM eNOS was 
incubated with CDK-1 for 50 minutes and CDK-2 and CDK-5 for 30 minutes. We observe that CDK 1 
does not significantly phosphorylate eNOS at ser600 when compared to either CDK 2 or CDK 5. It should 









Supplementary Figure 4 
 
Mass spectrometry of eNOS after immunoprecipitation with anti-P-ser600 antibody 
















Mass spectrometry of eNOS band after immunoprecipitation with our anti-P-ser600 antibody. 
Immunoprecipitation with our anti-P-ser600 antibody on HMEC lysates collected 45 minutes after RO-
3306 washout (blue) and untreated (white). The P-ser600 band (red) has reactivity with BD eNOS band 
(green) in the first elution. (TOP of figure) It should be noted ser602 (in the blot above) is bovine 
numbering whereas ser600 is human numbering. Detected eNOS fragments from mass spectrometry 









Table 3: NOS sequences used in phylogenetic study of phosphorylation sites 
Uniprot identifier Organism Length 
G1M5X2_AILME Ailuropoda melanoleuca 
(Giant panda) 
1208 
A0A3Q0SYZ0_AMPCI Amphilophus citrinellus 
(Midas cichlid) (Cichlasoma 
citrinellum) 
1428 




A0A2K5EWR1_AOTNA Aotus nancymaae (Ma's 
night monkey) 
1203 
A0A3P8QYB8_ASTCA Astatotilapia calliptera 
(Eastern happy) (Chromis 
callipterus) 
1428 
A0A383YRM3_BALAS Balaenoptera acutorostrata 
scammoni (North Pacific 
minke whale) (Balaenoptera 
davidsoni) 
1205 
A0A3Q1LSD1_BOVIN Bos taurus (Bovine) 1205 
F6VF63_CALJA Callithrix jacchus (White-
tufted-ear marmoset) 
1203 
A0A3Q7NHI9_CALUR Callorhinus ursinus 
(Northern fur seal) 
1203 
S9WKR6_CAMFR Camelus ferus (Wild bactrian 
camel) (Camelus bactrianus 
ferus) 
936 
F1PV05_CANLF Canis lupus familiaris (Dog) 
(Canis familiaris) 
1211 
A0A452EGA9_CAPHI Capra hircus (Goat) 1193 
H0V302_CAVPO Cavia porcellus (Guinea pig) 1206 
A0A2K5S0Y5_CEBCA Cebus capucinus imitator 1203 








A0A2K5IDK8_COLAP Colobus angolensis palliatus 
(Peters' Angolan colobus) 
1205 









A0A1S3G337_DIPOR Dipodomys ordii (Ord's 
kangaroo rat) 
1201 
A0A2Y9K7I3_ENHLU Enhydra lutris kenyoni 1202 
F6REP3_HORSE Equus caballus (Horse) 1204 




M3WID9_FELCA Felis catus (Cat) (Felis 
silvestris catus) 
1202 




A0A091D6A0_FUKDA Fukomys damarensis 
(Damaraland mole rat) 
(Cryptomys damarensis) 
1206 
V9ITD3_CHICK Gallus gallus (Chicken) 1146 
G3RKZ4_GORGO Gorilla gorilla gorilla 
(Western lowland gorilla) 
997 
A0A3P4RQQ4_GULGU Gulo gulo (Wolverine) 
(Gluton) 
997 




A0A0N8ETM2_HETGA Heterocephalus glaber 
(Naked mole rat) 
1206 
A0A3M0JYH6_HIRRU Hirundo rustica 1160 
NOS3_HUMAN Homo sapiens (Human) 1203 





W5MAD9_LEPOC Lepisosteus oculatus 
(Spotted gar) 
1123 
A0A340YEP3_LIPVE Lipotes vexillifer (Yangtze 
river dolphin) 
1205 
G3SZA3_LOXAF Loxodonta africana (African 
elephant) 
1199 






Macaca mulatta (Rhesus 
macaque) 
1205 





A0A2K5YFH5_MANLE Mandrillus leucophaeus 
(Drill) (Papio leucophaeus) 
1155 
A0A3P9CX80_9CICH Maylandia zebra (zebra 
mbuna) 
1428 
A0A1U7RHA5_MESAU Mesocricetus auratus 
(Golden hamster) 
1202 
F6S3S1_MONDO Monodelphis domestica 
(Gray short-tailed opossum) 
1193 
NOS3_MOUSE Mus musculus (Mouse) 1202 
M3Y867_MUSPF Mustela putorius furo 
(European domestic ferret) 
(Mustela furo) 
1211 
S7NFW7_MYOBR Myotis brandtii (Brandt's bat) 1213 
G1PQK0_MYOLU Myotis lucifugus (Little 
brown bat) 
1203 
A0A2Y9HAI4_NEOSC Neomonachus schauinslandi 
(Hawaiian monk seal) 
(Monachus schauinslandi) 
1202 









A0A0U1UVC9_OCHCU Ochotona curzoniae (Black-
lipped pika) 
1211 
A0A2U3WJA4_ODORO Odobenus rosmarus 
divergens (Pacific walrus) 
1207 
I3JWS0_ORENI Oreochromis niloticus (Nile 
tilapia) (Tilapia nilotica) 
1428 
D7RVB4_RABIT Oryctolagus cuniculus 
(Rabbit) 
1209 
H0X6T1_OTOGA Otolemur garnettii (Small-
eared galago) (Garnett's 
greater bushbaby) 
1434 
Q4U3W6_SHEEP Ovis aries (Sheep) 1205 
H2QVM2_PANTR Pan troglodytes 
(Chimpanzee) 
1203 
A0A096NXX3_PAPAN Papio anubis (Olive baboon) 1205 
A0A402FCB4_9SAUR Paroedura picta 1074 
A0A2Y9FMB5_PHYMC Physeter macrocephalus 





A0A2J8RKC7_PONAB Pongo abelii (Sumatran 
orangutan) (Pongo pygmaeus 
abelii) 
1203 





L5K1F9_PTEAL Pteropus alecto (Black flying 
fox) 
1200 
F1LQC7_RAT Rattus norvegicus (Rat) 1202 




A0A2K6PX93_RHIRO Rhinopithecus roxellana 
(Golden snub-nosed monkey) 
(Pygathrix roxellana) 
1205 
A0A2K6SCK8_SAIBB Saimiri boliviensis 
boliviensis (Bolivian squirrel 
monkey) 
1203 




Q7YSG7_PIG Sus scrofa (Pig) 1205 
A0A1U7UF18_TARSY Tarsius syrichta (Philippine 
tarsier) 
1200 
A0A2Y9DDV9_TRIMA Trichechus manatus 
latirostris (Florida manatee) 
1208 
L9KPE7_TUPCH Tupaia chinensis (Chinese 
tree shrew) 
1213 
A0A452SJK1_URSAM Ursus americanus (American 
black bear) (Euarctos 
americanus) 
1202 
A0A3Q7TG73_URSAR Ursus arctos horribilis 1201 
A0A384BW74_URSMA Ursus maritimus (Polar bear) 
(Thalarctos maritimus) 
1198 
A0A3Q7RVW8_VULVU Vulpes vulpes (Red fox) 1204 
Q800E5_XENLA Xenopus laevis (African 
clawed frog) 
1419 
F6VMJ0_XENTR Xenopus tropicalis (Western 








Table of Buffers and Recipes 
Protocol Buffer Recipe/Composition 
Immunofluorescence Blocking buffer/washing 
buffer 
5% horse serum, 0.3% 
Triton X-100, and 0.01% 
sodium azide in PBS. 
Flow Cytometry Wash buffer 0.5% BSA in PBS 
Blocking buffer 3% BSA, 0.1% Triton X-
100, and 100 μg/mL 
RNase A in PBS. 
Western Blotting Wash buffer In house TBST 







Table of Primary and Secondary Antibodies and Antibody Dilutions 
Protocol Name Type Dilution Manufacturer – 
catalog # 
IF Rabbit eNOS p602 or p600 Primary 1:200  
Rat Histone H3 s28 phospho Primary 1:100 Abcam – ab10543 
Rabbit eNOS Primary 1:100 Santa Cruz – SC654 
Mouse eNOS Primary 1:100 BD - 610297 
Mouse Vimentin Primary 1:100 Santa Cruz – SC-6260 
Donkey anti-Mouse 555 Secondary 1:500 Invitrogen - A32773 
Goat anti-Rabbit 488 Secondary 1:250 Invitrogen - A-11034 
Donkey anti-Rat 568 Secondary 1:750 Abcam - ab175475 
Flow 
Cytometry 
Rabbit eNOS p602 Primary 1:200  
Mouse eNOS-647 Primary 20 μL/ 
100k 
cells 
BD - 560102 
Donkey anti-rabbit 647 Secondary 1:2000 Abcam - ab150075 
Western 
Blotting 
Mouse eNOS Primary 1:1000 BD - 610297 
Rabbit ERK Primary 1:1000 CST – CST 9102 
Mouse P-ERK Primary 1:2000 CST – CST 9106 
Rabbit p38 Primary 1:1000 CST – CST 9212 
Mouse P-p38 Primary 1:2000 CST – CST 9216 
Rabbit P-JNK Primary 1:1000 CST – CST 9251 
Goat GAPDH Primary 1:1000 Abcam – ab9483 
Rabbit eNOS P-s1177 Primary 1:1000 R&D systems - 
MAB9028 
Rabbit eNOS P-s615 Primary 1:500 Abcam - ab138458 
Rabbit eNOS P-t495 Primary 1:1000 CST – CST 9574 
Mouse eNOS P-s632 Primary  1:1000 Abcam – ab76199 
Rabbit eNOS P-s114 Primary 1:1000 Millipore – 07-357 
 
